BSG and hepatocellular carcinoma: The safety and clinical activity of CD147‐targeting CAR‐T treatment are currently analyzed in phase I clinical trials for patients with recurrent glioblastoma (NCT04045847) and advanced hepatocellular carcinoma (NCT03993743).